| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Pathology, Molecular Neuro-Oncology Laboratory, Molecular Pathology Unit and Cancer Center, Massachusetts General Hospital and Harvard Medical School; 2 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; and 3 Department of Neuropathology, Heinrich-Heine-University, Dusseldorf, Germany
Requests for reprints: David N. Louis, Molecular Pathology Unit, 149-7151, Massachusetts General Hospital-East, 149 Thirteenth Street, Charlestown, MA 02129. Phone: 617-726-5690; Fax: 617-726-5684; E-mail: dlouis{at}partners.org.
Aberrant AKT (protein kinase B) signaling is common in many cancers, including glioblastoma. Current models suggest that AKT acts directly, or indirectly via the TSC complex, to activate the mammalian target of rapamycin (mTOR) as the main downstream mediator of AKT signaling. mTOR activation results in subsequent activation of S6K and STAT3, as well as suppression (i.e., phosphorylation) of 4E-BP1, leading to cell cycle progression and inhibition of apoptosis. Most studies of this pathway have used in vitro systems or tumor lysate–based approaches. We aimed to delineate these pathways in a primarily in situ manner using immunohistochemistry in a panel of 29 glioblastomas, emphasizing the histologic distribution of molecular changes. Within individual tumors, increased expression levels of p-TSC2, p-mTOR, p-4E-BP1, p-S6K, p-S6, and p-STAT3 were found in regions defined by elevated AKT activation. However, only TSC2, S6K, and S6 activation levels correlated significantly with AKT activation and clustered together in multidimensional scaling analyses. Ki-67 proliferation indices were significantly elevated in p-AKT-overexpressing regions, whereas expression of the apoptosis marker cleaved caspase 3 was generally low and not significantly different between the regions. These findings provide the first in vivo evidence for a close correlation between AKT and TSC2 phosphorylation levels in glioblastoma. Moreover, they suggest that downstream p-AKT effects are primarily mediated by S6 kinase signaling, thus enhancing proliferation rather than inhibiting apoptosis. (Cancer Res 2006; 66(11): 5618-23)
This article has been cited by other articles:
|
|
 |
|
  E. A. Goncharova, D. A. Goncharov, G. Damera, O. Tliba, Y. Amrani, R. A. Panettieri Jr., and V. P. Krymskaya Signal Transducer and Activator of Transcription 3 Is Required for Abnormal Proliferation and Survival of TSC2-Deficient Cells: Relevance to Pulmonary Lymphangioleiomyomatosis Mol. Pharmacol., October 1, 2009; 76(4): 766 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. ANNOVAZZI, M. MELLAI, V. CALDERA, G. VALENTE, L. TESSITORE, and D. SCHIFFER mTOR, S6 and AKT Expression in Relation to Proliferation and Apoptosis/Autophagy in Glioma Anticancer Res, August 1, 2009; 29(8): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marsh, P. Mukherjee, and T. N. Seyfried Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2-Deficient Mouse Astrocytoma Clin. Cancer Res., December 1, 2008; 14(23): 7751 - 7762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Nakamura, E. Garcia, and R. O. Pieper S6K1 Plays a Key Role in Glial Transformation Cancer Res., August 15, 2008; 68(16): 6516 - 6523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yang, M. J. Clarke, B. L. Carlson, A. C. Mladek, M. A. Schroeder, P. Decker, W. Wu, G. J. Kitange, P. T. Grogan, J. M. Goble, et al. PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel Clin. Cancer Res., June 15, 2008; 14(12): 3993 - 4001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Hjelmeland, K. P. Lattimore, B. E. Fee, Q. Shi, S. Wickman, S. T. Keir, M. D. Hjelmeland, D. Batt, D. D. Bigner, H. S. Friedman, et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion Mol. Cancer Ther., September 1, 2007; 6(9): 2449 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Sandsmark, H. Zhang, B. Hegedus, C. L. Pelletier, J. D. Weber, and D. H. Gutmann Nucleophosmin Mediates Mammalian Target of Rapamycin-Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes Cancer Res., May 15, 2007; 67(10): 4790 - 4799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lehman, B. Ledford, M. Di Fulvio, K. Frondorf, L. C. McPhail, and J. Gomez-Cambronero Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR FASEB J, April 1, 2007; 21(4): 1075 - 1087. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
